Clinical Trial Update: Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial evaluating CAR19 regulatory T cells (CAR19-tTreg) for relapsed/refractory CD19+ B-cell acute lymphoblastic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CAR19-tTreg

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Lymphoma Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN